Ablexis inks antibody licensing deal with pharma consortium; Ablynx chief won't rule out takeover; Love is a drug

 @FierceBiotech: After FDA's ARNA decision, what's next for obesity drugs? Article | Follow @FierceBiotech

 @JohnCFierce: PR on the Kadmon/Waksal deal for Three Rivers. Having $200M in investor cash means never having to say you're sorry. News | Follow @JohnCFierce

Special Report: Pharma's Biggest Flops

Special Report: Top 10 Phase III Failures of 2010

> In an intriguing new deal package, San Francisco-based Ablexis announced that a consortium of pharma companies--including five of the world's top outfits--had signed up to provide an unspecified seven-figure upfront in exchange for rights to use its AlivaMab Mouse technology for antibody discovery work. Upon delivery of the AlivaMab Mouse strains, Ablexis is entitled to receive an eight-figure payment from each consortium member, a group which includes Pfizer. Ablexis release

> In a review of its pipeline strategy, Ablynx CEO Edwin Moses told analysts that the company will hunt for new partners for its tiny antibody fragment technology, but he didn't rule out a takeover. Story

> Ariad Pharmaceuticals announced yesterday that its experimental drug ridaforolimus produced promising efficacy data in a mid-stage study for advanced uterine cancer but added that the side effects demonstrated by patients were worse than those among a group taking standard therapy. Report

>TransPharma Medical, which is developing drugs utilizing an active transdermal drug delivery technology, announced successful results of a 4-week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis. TransPharma release

And Finally... Love really is a drug. Researchers at Syracuse University found falling in love only takes about a fifth of a second and produces the same euphoria as cocaine. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.